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Dear Editor,
In Spring 2020, with our colleagues at The Vision Academy
[1], we identified the need for clinician guidance on how best
to communicate with patients and caregivers to ensure crucial
eye care appointments and services were continued during the
current COVID-19 pandemic. At that time, we noted, in par-
ticular, heightened anxiety levels among patients, receiving
intravitreal injections of anti-vascular endothelial growth fac-
tor (VEGF) for neovascular age-related macular degeneration
(nAMD), who need to attend regular ophthalmology appoint-
ments to maintain their vision. We therefore published guid-
ance for managing such patients during the acute phase of the
COVID-19 pandemic [2] and supported this with a patient
communication template. The communication could be sent
via e-mail, post, or text messages ahead of appointments to
reassure patients and caregivers that their safety and eye health
remained a priority [3].
Since then, the COVID-19 pandemic has escalated: clearly,
it is not going to disappear quickly, and we need to make the
necessary adjustments to establish a routine of safely treating
patients while the pandemic is ongoing. Evidence has
emerged that people with moderate/severe visual impact are
significantly more likely to experience worsened mental
health because of COVID-19-related restrictions than those
with mild/no visual impairment [4]. Additionally, a UK study
found that approximately 50% of patients with nAMD failed
to attend a scheduled hospital or clinic appointment [5]. Of
those non-attendees, 85% said they were fearful of contracting
COVID-19, and over 70% would have attended if they had
been given clear advance information of adequate infection
control measures. These findings are understandable given
patients with nAMD are at increased risk of COVID-19-
related complications, hospitalization, and mortality because
of increased age with comorbid conditions. They also rein-
force the need for patient information tools.
We now provide greater detail about the implementation of
patient guidance according to the local epidemic situation,
based on three (risk) tiers, until such time that long-term so-
lutions (e.g., effective vaccine) are available [6]:
1. The effective reproduction number, Rt, is < 1, but herd
immunity through mass vaccination has not yet been
achieved
2. Rt is ≈ 1, and local COVID-19-positive clusters result in a
relatively high risk of contracting COVID-19, although
local hospital resources are not critically overwhelmed
3. Rt is > 1, and hospital resources are under current or
imminent risk of significant pressure, with higher number
of local or national restrictions likely
For each scenario, we provide guidance on prioritizing
patients according to clinical need, while minimizing risk for
patients and healthcare professionals.
The Vision Academy has also endorsed a new ‘Dear
Patient’ letter and two accompanying infographics with the
goals of clear communication to minimize patient/caregiver
anxiety and maximize clinic attendance. Three color-coded
tiers (green, yellow or red) indicate simply the level of risk
and, most importantly, the precautions that are in place to
ensure the safety of patients and their caregivers (Fig. 1). It
is very important that appointments are not missed especially
during treatment phases.
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Educational material in the form of infographic patient
factsheets highlights characteristics for each of the three risk
scenarios (and include an Amsler Grid) and provide patients
with information on maintaining and improving their mental
wellbeing alongside their eye health.When patients are unable
to attend the clinic, they must re-schedule the appointment as
quickly as possible and monitor their vision in the meantime.
Should any change in their vision occur, patients are asked to
re-contact the clinic.
We encourage the ophthalmic community to download
these patient materials from https://www.visionacademy.org/
vision-academy-community/COVID-19-materials and adapt
them for local use. Regionally, campaigns to call patients
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Description of tiers Summary of main adaptations to clinic procedures
Rates of infection remain at a low level
Public health measures are less restricted but 
social distancing measures remain critical
Clinic staff are regularly tested as appropriate
Patients and accompanying individuals are asked to wear a mask
Appointments may be rescheduled if patients are unwell
Number of people allowed in the waiting room may be limited
Appointments will be brief and some regular tests might sometimes be skipped
Increase in infection rates
New public health measures implemented
As green plus:
Regular eye examinations might be skipped, although treatment would be given
Some injection schedules may be changed to avoid additional monitoring
Some non-essential / non-urgent appointments may be postponed
High rates of infection
Strict public health measures have been 
implemented
As green and yellow plus:
A pre-appointment telephone or video call may be required to see if the clinic 
visit is essential or if the appointment can be postponed
Patients requiring regular treatment to preserve sight will be prioritized
Non-urgent appointments will be re-scheduled 
All patients should regularly monitor vision at home and contact the clinic immediately if vision changes
Fig. 1 Description of main clinic procedural adaptations during the COVID-19 pandemic according to local epidemic situation, summarized from the
patient infographic
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